Aerovate Therapeutics Investors: Investigation on behalf of investors; the Portnoy Law Firm
Aerovate Therapeutics, Inc. (AVTE)
Company Research
Source: GlobeNewswire
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, June 20, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Aerovate Therapeutics, Inc. (“Aerovate” or the “Company”) (Nasdaq: AVTE) investors that a class action has been filed on behalf of investors. Aerovate investors that lost money on their investment are encouraged to contact Lesley Portnoy, Esq. Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: lesley@portnoylaw.com, to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses. Shares of Aerovate Therapeutics are down 90.1% following the release of poor top line results from its Phase 2b portion of IMPAHCT evaluating AV-101 for the treatment of pulmonary arterial hypertension. Block & Leviton is investigating wh
Show less
Read more
Impact Snapshot
Event Time:
AVTE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AVTE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AVTE alerts
High impacting Aerovate Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
AVTE
News
- Investigation Into Aerovate Therapeutics, Inc. (AVTE) Announced byHolzer & Holzer, LLCGlobeNewswire
- Aerovate (AVTE) Down as Lead Drug Fails to Meet PAH Study Goals [Yahoo! Finance]Yahoo! Finance
- Aerovate Therapeutics, Inc. (NASDAQ: AVTE) was downgraded by analysts at Evercore ISI from an "outperform" rating to an "inline" rating. They now have a $2.00 price target on the stock, down previously from $27.00.MarketBeat
- Aerovate Therapeutics, Inc. (NASDAQ: AVTE) was downgraded by analysts at TD Cowen from a "buy" rating to a "hold" rating.MarketBeat
- Aerovate Therapeutics, Inc. (NASDAQ: AVTE) was downgraded by analysts at Wells Fargo & Company from an "overweight" rating to an "equal weight" rating. They now have a $2.00 price target on the stock, down previously from $35.00.MarketBeat
AVTE
Earnings
- 11/13/23 - Miss
AVTE
Sec Filings
- 6/28/24 - Form 8-K
- 6/20/24 - Form SC
- 6/20/24 - Form 4
- AVTE's page on the SEC website